SAGE Therapeutics (SAGE) Stock Forecast & Price Target

Compare

940 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SAGE Analyst Ratings

Hold

0 Buy

9 Hold

1 Sell

Based on 10 analysts giving stock ratings to

SAGE

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SAGE Stock 12 Month Forecast

Average Price Target

$8.60

▼(-0.92% Downside)

Based on 10 Wall Street analysts offering 12 month price targets for SAGE Therapeutics in the last 3 months. The average price target is $8.60 with a high forecast of $12.00 and a low forecast of $5.00. The average price target represents a -0.92% change from the last price of $8.68.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","13":"$13","6.25":"$6.25","8.5":"$8.5","10.75":"$10.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,6.25,8.5,10.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.08,9.304615384615385,9.52923076923077,9.753846153846155,9.978461538461538,10.203076923076923,10.427692307692308,10.652307692307692,10.876923076923077,11.10153846153846,11.326153846153847,11.55076923076923,11.775384615384615,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.08,9.043076923076923,9.006153846153847,8.96923076923077,8.932307692307692,8.895384615384616,8.858461538461539,8.821538461538461,8.784615384615384,8.747692307692308,8.71076923076923,8.673846153846153,8.636923076923077,{"y":8.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.08,8.766153846153847,8.452307692307693,8.138461538461538,7.8246153846153845,7.510769230769231,7.196923076923078,6.883076923076923,6.569230769230769,6.2553846153846155,5.941538461538462,5.627692307692308,5.313846153846154,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.11,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.03,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.76,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.96,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.05,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 44, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.79,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.43,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.25,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.3,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.86,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.48,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.62,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.08,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$12.00

Average Price Target$8.60

Lowest Price Target$5.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

Hold

3.69%

Upside

Reiterated

08/01/25

SAGE's overall stock score reflects the balance between financial challenges and positive strategic developments. The merger offers promising long-term benefits, but ongoing profitability and cash flow issues remain significant concerns.

Laura ChicoWedbush

Wedbush

$8.5

Hold

-2.07%

Downside

Reiterated

07/31/25

Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (NASDAQ: SAGE) and ZimVie Inc (NASDAQ: ZIMV)

Joel BeattyRobert W. Baird

Robert W. Baird

$7→$9

Hold

3.69%

Upside

Reiterated

06/20/25

Sage Therapeutics price target raised to $9 from $7 at BairdSage Therapeutics price target raised to $9 from $7 at Baird

Anupam RamaJ.P. Morgan

J.P. Morgan

$11→$8.5

Hold

-2.07%

Downside

Reiterated

06/20/25

J.P. Morgan Remains a Hold on SAGE Therapeutics (SAGE)

Ritu BaralTD Cowen

TD Cowen

$9→$8.5

Hold

-2.07%

Downside

Reiterated

06/17/25

TD Cowen Sticks to Their Hold Rating for SAGE Therapeutics (SAGE)

Douglas TsaoH.C. Wainwright

H.C. Wainwright

$12

Hold

38.25%

Upside

Reiterated

06/17/25

H.C. Wainwright Keeps Their Hold Rating on SAGE Therapeutics (SAGE)

David AmsellemPiper Sandler

Piper Sandler

$9→$8.5

Hold

-2.07%

Downside

Downgraded

06/17/25

Sage Therapeutics downgraded to Neutral from Overweight at Piper SandlerSage Therapeutics downgraded to Neutral from Overweight at Piper Sandler

Vikram PurohitMorgan Stanley

Morgan Stanley

$9→$8.5

Hold

-2.07%

Downside

Reiterated

06/17/25

Hold Rating on SAGE Therapeutics Amid Acquisition Offer and CVR Uncertainties

Sumant KulkarniCanaccord Genuity

Canaccord Genuity

$8→$8.5

Hold

-2.07%

Downside

Reiterated

06/16/25

Hold Rating on SAGE Therapeutics Amid Uncertainty and Acquisition Developments

Brian AbrahamsRBC Capital

RBC Capital

$7→$9

Hold

3.69%

Upside

Reiterated

06/16/25

Analysts' Top Healthcare Picks: Surgery Partners (SGRY), SAGE Therapeutics (SAGE)

Tazeen AhmadBank of America Securities

Bank of America Securities

Sell

-42.40%

Downside

Reiterated

05/19/25

Bank of America Securities Sticks to Their Sell Rating for SAGE Therapeutics (SAGE)

Ami FadiaNeedham

Needham

―

Hold

―

Reiterated

04/30/25

Cautious Hold Rating on SAGE Therapeutics Amid Uncertain Growth Prospects

Marc GoodmanLeerink Partners

Leerink Partners

Hold

-7.83%

Downside

Reiterated

04/29/25

SAGE Therapeutics: Hold Rating Maintained Amid Steady Growth and Strategic Uncertainties

Uy EarMizuho Securities

Mizuho Securities

Hold

3.69%

Upside

Reiterated

04/29/25

SAGE Therapeutics (SAGE) Gets a Hold from Mizuho Securities

Paul MatteisStifel Nicolaus

Stifel Nicolaus

Hold

-30.88%

Downside

Reiterated

02/12/25

SAGE Therapeutics (SAGE) Receives a Hold from Stifel Nicolaus

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

Hold

3.69%

Upside

Reiterated

08/01/25

Laura ChicoWedbush

Wedbush

$8.5

Hold

-2.07%

Downside

Reiterated

07/31/25

Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (NASDAQ: SAGE) and ZimVie Inc (NASDAQ: ZIMV)

Joel BeattyRobert W. Baird

Robert W. Baird

$7→$9

Hold

3.69%

Upside

Reiterated

06/20/25

Sage Therapeutics price target raised to $9 from $7 at BairdSage Therapeutics price target raised to $9 from $7 at Baird

Anupam RamaJ.P. Morgan

J.P. Morgan

$11→$8.5

Hold

-2.07%

Downside

Reiterated

06/20/25

J.P. Morgan Remains a Hold on SAGE Therapeutics (SAGE)

Ritu BaralTD Cowen

TD Cowen

$9→$8.5

Hold

-2.07%

Downside

Reiterated

06/17/25

TD Cowen Sticks to Their Hold Rating for SAGE Therapeutics (SAGE)

Douglas TsaoH.C. Wainwright

H.C. Wainwright

$12

Hold

38.25%

Upside

Reiterated

06/17/25

H.C. Wainwright Keeps Their Hold Rating on SAGE Therapeutics (SAGE)

David AmsellemPiper Sandler

Piper Sandler

$9→$8.5

Hold

-2.07%

Downside

Downgraded

06/17/25

Sage Therapeutics downgraded to Neutral from Overweight at Piper SandlerSage Therapeutics downgraded to Neutral from Overweight at Piper Sandler

Vikram PurohitMorgan Stanley

Morgan Stanley

$9→$8.5

Hold

-2.07%

Downside

Reiterated

06/17/25

Hold Rating on SAGE Therapeutics Amid Acquisition Offer and CVR Uncertainties

Sumant KulkarniCanaccord Genuity

Canaccord Genuity

$8→$8.5

Hold

-2.07%

Downside

Reiterated

06/16/25

Hold Rating on SAGE Therapeutics Amid Uncertainty and Acquisition Developments

Brian AbrahamsRBC Capital

RBC Capital

$7→$9

Hold

3.69%

Upside

Reiterated

06/16/25

Analysts' Top Healthcare Picks: Surgery Partners (SGRY), SAGE Therapeutics (SAGE)

Tazeen AhmadBank of America Securities

Bank of America Securities

Sell

-42.40%

Downside

Reiterated

05/19/25

Bank of America Securities Sticks to Their Sell Rating for SAGE Therapeutics (SAGE)

Ami FadiaNeedham

Needham

―

Hold

―

Reiterated

04/30/25

Cautious Hold Rating on SAGE Therapeutics Amid Uncertain Growth Prospects

Marc GoodmanLeerink Partners

Leerink Partners

Hold

-7.83%

Downside

Reiterated

04/29/25

SAGE Therapeutics: Hold Rating Maintained Amid Steady Growth and Strategic Uncertainties

Uy EarMizuho Securities

Mizuho Securities

Hold

3.69%

Upside

Reiterated

04/29/25

SAGE Therapeutics (SAGE) Gets a Hold from Mizuho Securities

Paul MatteisStifel Nicolaus

Stifel Nicolaus

Hold

-30.88%

Downside

Reiterated

02/12/25

SAGE Therapeutics (SAGE) Receives a Hold from Stifel Nicolaus

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering SAGE Therapeutics

1 Month

xxx

Success Rate

11/18 ratings generated profit

Average Return

-1.03%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 61.11% of your transactions generating a profit, with an average return of -1.03% per trade.

3 Months

xxx

Success Rate

12/18 ratings generated profit

Average Return

+2.63%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +2.63% per trade.

1 Year

Tazeen AhmadBank of America Securities

Success Rate

6/18 ratings generated profit

Average Return

-19.37%

reiterated a sell rating 3 months ago

Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -19.37% per trade.

2 Years

xxx

Success Rate

5/18 ratings generated profit

Average Return

-27.48%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 27.78% of your transactions generating a profit, with an average return of -27.48% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SAGE Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SAGE has received 1 Buy Ratings, 19 Hold Ratings, and 1 Sell Ratings. SAGE average Analyst price target in the past 3 months is 8.60.

Each month's total comprises the sum of three months' worth of ratings.

SAGE Financial Forecast

SAGE Earnings Forecast

Next quarter’s earnings estimate for SAGE is -$0.74 with a range of -$0.96 to -$0.10. The previous quarter’s EPS was -$0.79. SAGE beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.44% of the time in the same period. In the last calendar year SAGE has Preformed in-line its overall industry.

SAGE Sales Forecast

Next quarter’s sales forecast for SAGE is $27.82M with a range of $16.73M to $72.60M. The previous quarter’s sales results were $31.66M. SAGE beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.90% of the time in the same period. In the last calendar year SAGE has Preformed in-line its overall industry.

SAGE Stock Forecast FAQ

What is SAGE’s average 12-month price target, according to analysts?

Based on analyst ratings, SAGE Therapeutics, Inc. (US)’s 12-month average price target is 8.60.

What is SAGE’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for SAGE, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SAGE a Buy, Sell or Hold?

SAGE Therapeutics, Inc. (US) has a consensus rating of Hold which is based on 0 buy ratings, 9 hold ratings and 1 sell ratings.

What is SAGE Therapeutics, Inc. (US)’s price target?

The average price target for SAGE Therapeutics, Inc. (US) is 8.60. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $12.00 ,the lowest forecast is $5.00. The average price target represents -0.92% Decrease from the current price of $8.68.

What do analysts say about SAGE Therapeutics, Inc. (US)?

SAGE Therapeutics, Inc. (US)’s analyst rating consensus is a Hold. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of SAGE?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

SAGE Therapeutics (SAGE) Stock Forecast & Price Target

SAGE Analyst Ratings

SAGE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering SAGE Therapeutics

SAGE Analyst Recommendation Trends

SAGE Financial Forecast

SAGE Earnings Forecast

SAGE Sales Forecast

SAGE Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts